Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Anticancer drugs

Imatinib hits anaplastic large cell lymphoma

Nature Reviews Drug Discovery volume 11, page 908 (2012)Cite this article

Subjects

Access through your institution
Buy or subscribe

This study characterized a new signalling pathway in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-triggered lymphoma. The authors showed that the transcription factors JUN and JUNB promote lymphoma development and tumour dissemination through transcriptional regulation of platelet-derived growth factor receptor B (PDGFRB). Inhibition of PDGFRB with imatinib prolonged the survival of NPM-ALK transgenic mice and increased the efficacy of the ALK-specific inhibitor crizotinib in transplanted NPM-ALK tumours. In a patient with refractory late-stage NPM-ALK-positive lymphoma, imatinib produced a rapid, complete and sustained remission.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Laimer, D. et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature Med. 18, 1699–1704 (2012)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Charlotte Harrison
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, C. Imatinib hits anaplastic large cell lymphoma. Nat Rev Drug Discov 11, 908 (2012). https://doi.org/10.1038/nrd3902

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd3902

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer